CTOs on the Move

Novis Pharmaceuticals

www.novispharma.com

 
Novis Pharmaceuticals is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Absolute Biotech

Absolute Biotech is a company that specializes in antibody reagents, kits, and services, adding value to existing antibodies through annotation, validation, sequencing, engineering, and recombinant manufacturing.

Ajinomoto AminoScience

Ajinomoto AminoScience is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NightstaRx

Nightstar is a private biopharmaceutical company focused on the development of therapies for retinal dystrophies. The Company’s lead programme is a retinal gene therapy for choroideremia, a rare inherited cause of blindness that affects around 1 in 50,000 people. Gene therapy has the potential to be an effective treatment for choroideremia and a range of other retinal dystrophies. The Company’s lead investors are Syncona LLP and NEA Inc. Syncona is an evergreen investment company, taking an active role in identifying, supporting and developing technologies with the potential to impact significantly the healthcare market of the future. NEA is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies.

Unilens Vision

Unilens Vision is a Seminole, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deciphera

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the effectiveness of many cancer therapies. Our small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. We use our deep understanding of kinase biology together with a proprietary chemistry library to purposefully design compounds that maintain kinases in a “switched off” or inactivated conformation. Deciphera has developed a diverse pipeline of drug candidates designed to improve outcomes for patients with cancer by enhancing the quality, rate and/or durability of their responses to treatment.